Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
0.8858
-0.0142 (-1.58%)
Apr 23, 2026, 11:31 AM EDT - Market open
Skye Bioscience Employees
Skye Bioscience had 12 employees as of December 31, 2025. The number of employees decreased by 4 or -25.00% compared to the previous year.
Employees
12
Change (1Y)
-4
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$4,660,401
Market Cap
31.12M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 12 | -4 | -25.00% |
| Dec 31, 2024 | 16 | 5 | 45.45% |
| Dec 31, 2023 | 11 | 0 | - |
| Dec 31, 2022 | 11 | 2 | 22.22% |
| Dec 31, 2021 | 9 | 3 | 50.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Curis | 24 |
| Lisata Therapeutics | 21 |
| NeuroSense Therapeutics | 17 |
| Serina Therapeutics | 13 |
| AEON Biopharma | 8 |
| Neuphoria Therapeutics | 8 |
| NanoViricides | 7 |
| Lexaria Bioscience | 7 |
SKYE News
- 16 days ago - Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit - GlobeNewsWire
- 21 days ago - Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development - GlobeNewsWire
- 6 weeks ago - Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 - GlobeNewsWire
- 2 months ago - Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year - Benzinga
- 2 months ago - Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide - GlobeNewsWire
- 3 months ago - Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference - GlobeNewsWire
- 3 months ago - Skye Bioscience to Present Poster at Keystone Obesity Conference - GlobeNewsWire